NCT02226861View on ClinicalTrials.gov

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 26, 2014

Primary Completion Date

May 23, 2018

Study Completion Date

June 27, 2018

Conditions
Acute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)MDS
Interventions
DEVICE

CliniMACS CD34 selection system

Stem cells will be selected with the CliniMACS system before transplant.

BIOLOGICAL

ULD IL-2

sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02226861 - Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter